What is the MCRC Springboard Award?

With generous support from the CRUK Manchester Centre and Cancer Research Horizons, The Manchester Cancer Research Centre launched the Springboard Award to support early-stage innovations showing the greatest potential to deliver patient impact with a pump prime funding programme that will accelerate these projects to reaching their full potential.

Working with the commercialisation teams at both The University of Manchester Innovation Factory and Cancer Research Horizons, we will use the funding to launch exciting ideas and overcome the financial obstacles that academics typically face when translating an idea to a product or service.

Along with key funding, successful/selected projects will have access to an infrastructure of industry connections, commercial advice, and business-planning workshops.

Key themes of the projects include:

• Cancer Early Detection
• Radiotherapy BioAdaptation
• Cancer Biomarkers
• Digital Cancer Centre
• Integrative Pathology
• Experimental Cancer Medicine

Projects that have been funded by the award

Blood-based biomarker discovery for the diagnosis and early detection of Biliary Tract Cancers (BTC)

This work focusses primarily on overcoming the diagnostic challenge posed by Biliary Tract Cancer (BTC), a rare cancer with a rising worldwide incidence, which typically requires repeated costly and invasive biopsy procedures to diagnose. The translational project builds on an existing programme of work evaluating improved cancer diagnosis through blood-based biomarker detection. Wider application of the methodologies in this project for diagnosing BTC have the potential to be both prognostic and predictive in BTC management, with future potential for earlier cancer detection and screening in high-risk populations.

This work is a collaboration between the CRUK National Biomarker Centre, The Christie NHS Foundation Trust and MCRC Biobank.

Project leads: 

• Dr Alicia-Marie Conway, Academic Clinical Lecturer, The University of Manchester and CRUK National Biomarker Centre
• Dr Alexandra Clipson, Staff Scientist, Deputy Team Leader of the Nucleic Acid Biomarkers Team, CRUK Cancer Biomarker Centre

Investigating the use of liver function MR images for bio-adaption in radiotherapy

Liver function can be a major complication associated with liver radiotherapy. Liver function is currently assessed based on clinical symptoms, biopsy and blood parameters, which can be respectively quite subjective, invasive and time-consuming. This team is working to demonstrate the feasibility of using a non-invasive imaging technique to assess liver function in radiotherapy treated patients. They will investigate if changes in liver function are seen during the treatment, and if there is a correlation with the radiotherapy dose. The results from this study will provide data on how these images could be used on the MR-Linac to adapt a patient’s treatment to take account of their liver function in real time, ultimately reducing the number of patients who suffer from complications, improving treatments and outcomes.

Project lead: 

• Dr Robert Chuter, Principal Clinical Scientist at The Christie NHS Foundation Trust and Honorary Lecturer at The University of Manchester

Next-generation phantoms for MRI-Linac guided radiotherapy

Image-guided radiotherapy, particularly MR-Linac (magnetic-resonance-linear-accelerator), can transform treatment outcomes in several challenging cancers. Phantoms, manufactured objects that mimic the response of tissues to imaging and radiotherapy, are critical for future development of these techniques. For example, they can be imaged under irradiation for long periods, which is impossible with human volunteers. However, current phantoms don’t accommodate tissue movement or deformation. This team are developing phantoms that mimic tissue and tumour motion from respiration, enabling the development of more precise radiotherapy guidance, concentrating dose in the tumour and minimising dose to healthy tissue. Their initial focus is on improving radiotherapy treatments for non-small-cell lung cancer, in which developments are particularly hampered by the lack of realistic phantoms.

Project leads: 

• Professor Brian Derby, Professor of Materials Science, The University of Manchester
• Dr Stephen Edmondson, Senior Lead in Polymer Chemistry, The University of Manchester

Comparison of gene-derived and oxygen-enhanced MRI-derived hypoxia markers in head and neck cancer

Hypoxia, a state of low oxygen, is a hallmark of solid tumours and an indicator of poor prognosis and resistance to radiotherapy, chemotherapy, targeted therapies and immunotherapy. Tumour hypoxia is a dynamic process (tumours become more- or less-hypoxic over time), and at present there is no way to track hypoxia during the treatment pathway in clinical practice. This team has been working on methods to image regions of hypoxia, using oxygen-enhanced MRI, in patients with head and neck cancer. The technique has the potential for areas of hypoxia to be identified and in turn, such areas could be dose-boosted to improve local control, or for the identification of less hypoxic tumours, which could undergo radiotherapy de-escalation. We now aim to incorporate biological validation by comparing OE-MRI derived parameters with a tumour derived 26-gene hypoxia signature that is specific to HNC.

Project lead: 

• Michael Dubec, Principal Clinical Scientist at The Christie NHS Foundation Trust and PhD student at The University of Manchester